These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8284635)

  • 21. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
    Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
    Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
    Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
    Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The reliability of highly elevated CA 19-9 levels.
    Osswald BR; Klee FE; Wysocki S
    Dis Markers; 1993 Dec; 11(5-6):275-8. PubMed ID: 8082316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of routine biochemical tests in discriminating between malignant and benign pancreatic tumours.
    Athlin L; Blind PJ; Eriksson S
    HPB Surg; 1991 Jun; 4(2):147-53; discussion 153-5. PubMed ID: 1931781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50.
    Molina LM; Díez M; Cava MT; Maestro ML; Ortega MD; Mendíz JG; Prego A; De Diego JA; Balibrea JL
    Int J Biol Markers; 1990; 5(3):127-32. PubMed ID: 2286776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
    Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
    Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer.
    Pålsson B; Masson P; Andrén-Sandberg A
    Eur J Surg Oncol; 1997 Apr; 23(2):151-6. PubMed ID: 9158191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
    Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
    Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study.
    Collazos J; Genolla J; Ruibal A
    Clin Chim Acta; 1992 Sep; 210(1-2):145-51. PubMed ID: 1424156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.
    Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T
    Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CA 19.9 in biliopancreatic diseases.
    Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Loizate Totoricagüena A
    Int J Biol Markers; 1989; 4(1):51-2. PubMed ID: 2746047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.